Catalyst Wire Dossier Catalyst Wire Dossier

Apatinib Mesylate Tablets

Apatinib · Jiangsu HengRui Medicine Co., Ltd.
Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for Apatinib Mesylate Tablets, covering 2018-07-20 to 2025-01-24. Get the full timeline:

Most recent: Clinical Trial Update: A Trial of SHR3162 Combined With Apatinib Mesylate Tablets or SHR3162 Monotherapy in Patients With Metastatic Castration Resistant Prostate Cancer [Phase 2]

See pricing